Glaxo Smith Kline has been conducting Phase 3 trials on a malaria vaccine in Africa, which has been reported recently in New England Journal of Medicine. Dr. Satyajit Rath discusses with Newsclick the importance of such a vaccine and whether the results indicate that it would indeed be useful in the fight against malaria.